Latest Breaking News On - Repare therapeutics - Page 1 : vimarsana.com

Repare Therapeutics Announces Fast Track Designation Granted by the FDA for Lunresertib in Combination with Camonsertib for the Treatment of Platinum-Resistant Ovarian Cancer

Repare Therapeutics Announces Fast Track Designation Granted by the FDA for Lunresertib in Combination with Camonsertib for the Treatment of Platinum-Resistant Ovarian Cancer
financialpost.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialpost.com Daily Mail and Mail on Sunday newspapers.

United kingdomNew yorkUnited statesBritish columbiaSam mizrahiGwyn morganBarbara shecterMaria koehlerJoe oconnorJustin trudeauGabriel friedmanCompany nasdaqExchange commissionNational postDrug administrationA bank

Repare Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Repare Therapeutics Inc. , a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate in a fireside chat at the Goldman Sachs.

United statesGoldman sachsCompany nasdaqRepare therapeutics incRepare therapeuticsAnnual global healthcare conference

Repare Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Repare Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
financialpost.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialpost.com Daily Mail and Mail on Sunday newspapers.

Repare therapeutics incRepare therapeuticsInvestor relations

Repare Therapeutics (NASDAQ:RPTX) Rating Reiterated by HC Wainwright

Repare Therapeutics (NASDAQ:RPTX – Get Free Report)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research report issued on Thursday, Benzinga reports. They presently have a $10.00 target price on the stock. HC Wainwright’s price target would indicate a potential upside of 187.36% from the stock’s previous close. Separately, […]

United statesRepare therapeutics incExchange traded conceptsHarbor capital advisors incRepare therapeutics company profileConnor clark lunn investment management ltdBlackstone incRaymond james financial services advisors incRepare therapeuticsGet free reportBloom burtonJames financial services advisorsLunn investment managementTraded conceptsHarbor capital advisorsCapital advisors

Repare Therapeutics to Present Initial Phase 1 MINOTAUR Data at ESMO GI Congress 2024

Repare Therapeutics Inc. , a leading clinical-stage precision oncology company, announced initial data from the Phase 1 MINOTAUR study evaluating lunresertib in combination with FOLFIRI for the.

Lunresertib lunreZeva wainbergRepare therapeutics incEuropean society of medical oncologyGastrointestinal gi cancers congressCompany nasdaqDavid geffen school of medicineRepare therapeuticsEuropean societyMedical oncologyCancers congressAdvanced gastrointestinalDavid geffen school